Log on / register
Feedback | Support | My details
Clinical significance of BRAF mutations in metastatic melanoma.
Chang DZ, Panageas KS, Osman I, Polsky D, Busam K, Chapman PB
J Transl Med 2004 Dec 21, 2:46
[Full text] [PubMed] [Related articles]


printer friendly 
to  [Help]

PubMed Central articles that cite the above article:

1.
Sorafenib in advanced melanoma: a Phase II randomised discontinuation trial analysis.
Eisen T, Ahmad T, Flaherty KT, Gore M, Kaye S, Marais R, Gibbens I, Hackett S, James M, Schuchter LM, Nathanson KL, Xia C, Simantov R, Schwartz B, Poulin-Costello M, O'Dwyer PJ, Ratain MJ
Br J Cancer 2006 Sep 4, 95:581-6
 [PubMed Central] [PubMed] [Related articles]
2.
Improving melanoma classification by integrating genetic and morphologic features.
Viros A, Fridlyand J, Bauer J, Lasithiotakis K, Garbe C, Pinkel D, Bastian BC
PLoS Med 2008 Jun 3, 5:e120
 [PubMed Central] [PubMed] [Related articles]
3.
*** Unable to retrieve article 18532874 ***

 [PubMed Central] [PubMed] [Related articles]
4.
Utility of circulating B-RAF DNA mutation in serum for monitoring melanoma patients receiving biochemotherapy.
Shinozaki M, O'Day SJ, Kitago M, Amersi F, Kuo C, Kim J, Wang HJ, Hoon DS
Clin Cancer Res 2007 Apr 1, 13:2068-74
 [PubMed Central] [PubMed] [Related articles]
printer friendly 
to  [Help]
Terms and Conditions Privacy statement Information for advertisers Jobs at BMC Contact us
© 1999-2009 BioMed Central Ltd unless otherwise stated. Part of Springer Science+Business Media.